Краткий курс истории НПВП

1. <div><p>Vane J. The fight against rheumatism: from willow bark to COX-1 sparing drugs. J Physiol Pharmacol 2000;51(4 Pt 1):573-86.</p><p>Hebbes C., Lambert D. Non-opioid analgesics. Anaesth Intens Care Med 2011;12(2):69-72.</p><p>Brune K. The early history of non-opioid analgesics. Acute Pain 1997;1:33-40.</p><p>Pasero G., Marson P. A short history of anti-rheumatic therapy. II. Aspirin. Reumatismo 2010;62(2):148-56.</p><p>Schror K. 100 years of successful drug discovery. The history of aspirin. Pharm Unserer Zeit 2009;38(4):306-13.</p><p>Norn S., Permin H., Kruse P., Kruse E. From willow bark to acetylsalicylic acid. Dan Medicinhist Arbog 2009;37:79-98.</p><p>Reyburn H., Mtove G., Hendriksen I., Von Seidlein L. Oral quinine for the treatment of uncomplicated malaria. Brit J Med 2009;339:2066.</p><p>Харкевич Д.А. Фармакология. М.: Медицина, 1987.</p><p>Academy of Medicine: November 15, 1842. Treatment of rheumatism by the sulphate of quinine. Prov Med J Retrosp Med Sci 1842;5(113):175.</p><p>Jones H. Nitrate of potash and quinine as febrifuges. Br Med J 1873;1(635):224-5.</p><p>Боткин С.П. Об остром сочленовном ревматизме. Лекция четвертая. В кн.: Общие основы клинической медицины СПб., 1897 (цит. по: Боткин С.П. Клинические лекции. Т.2. М.: Медгиз, 1950).</p><p>Kaiser H. From the plant to chemistry - the early history of «rheumatic medication». Z Rheumatol 2008;67(3):252-62.</p><p>Stone E. An account of the success of the bark of the willow in the cure of agues. Philosophical Transactions 1764;53:195-200.</p><p>Foster B. Clinical remarks on a case of acute rheumatism treated by salicin. Br Med J 1876;2(832):746-7.</p><p>Maclagan T. The treatment of acute rheumatism by salicin. Lancet 1876;1:342-3 &amp; 383-4 (цит по: Volmink J. (2005). The willow as a Hottentot (Khoikhoi) remedy for rheumatic fever. JLL Bulletin: Commentaries on the history of treatment evaluation. http://www. jameslindlibrary.org).</p><p>Marson P., Pasero G. The Italian contributions to the history of salicylates. Reumatismo 2006;58(1):66-75.</p><p>Lafont O. From the willow to aspirin. Rev Hist Pharm (Paris) 2007;55(354):209-16.</p><p>Lindsey A., Jeskey H. The Kolbe-Schmitt reaction. Chem Rev 1957;57(4):583-620.</p><p>Cash J. Introduction to a discussion on carbolic acid and its allies, including antipyrin and antifebrin. Br Med J 1888;2(1453):975-82.</p><p>Brogden R. Pyrazolone derivatives. Drugs 1986;32(Suppl. 4):60-70.</p><p>Аминофеназон. http://ru.wikipedia.org</p><p>Norregaard S. The use of pyramidon in the treatment of rheumatic fever. Acta Med Scand 1947;128(5):486-8.</p><p>Bologna N., Alcozer G. Endovenous therapy with aminophenazone of rheumatic and articular diseases. Arch Maragliano Patol Clin 1950;5(6):1279-93.</p><p>Andres G., Farinella A. Amidopyrine gentisate in the treatment of rheumatism. Minerva Med 1956;47(3-4):50-2.</p><p>Leibowitz S. Fatal agranulocytosis following ingestion of aminopyrine. N Y State J Med 1948;48(16):1838-40.</p><p>Brunner D., Schindell E. Relationship between derivatives of amidopyrine and agranulocytosis. Sang 1954;25(9):983-9.</p><p>Плоткин В. Острое отравление пирамидоном. Тер арх 1965;37(9):112-4.</p><p>Myslak Z., Musialowicz E. Pyramidon toxicity: analysis of 36 cases of acute poisoning. Pol Tyg Lek 1972;27(1):16-9.</p><p>Metamizole. http://en.wikipedia.org/wiki/Metamizole</p><p>Edwards J., Meseguer F., Faura C. et al. Single-dose dipyrone for acute postoperative pain. Cochrane Database Syst Rev 2001;3:CD003227.</p><p>Anonymous. Amynopyrine, dipyrone and agranulocytosis. Canad Med Ass J 1964;91:1229-30.</p><p>Garcia S., Canoniero M., Lopes G., Soriano A. Metamizole use among Hispanics in Miami: report of a survey conducted in a primary care setting. South Med J 2006;99(9):924-6.</p><p>Ушкалова Е.А., Астахова А.В. Проблемы безопасности анальгина. Фарматека 2003;1(64):53-7.</p><p>Hamerschlak N., Cavalcanti A. Neutropenia, agranulocytosis and dipyrone. Sao Paulo Med J 2005;123(5):247-9.</p><p>The International Agranulocytosis and Aplastic Anemia Study. Risk of agranulocytosis and aplastic anemia study: relation to drug use with special reference to analgesics. JAMA 1986;256:1749-57.</p><p>Schonhofer P. Dipyrone (Metamizol): Restored to good repute? Internistische Praxis 1999;39:184-5. http://www.essentialdrugs.org/edrug</p><p>Phenylbutazone. http://en.wikipedia.org/wiki/Phenylbutazone</p><p>Kuzell W., Schaffarzick R., Brown B., Mankle E. Phenylbutazone (butazolidin) in rheumatoid arthritis and gout. J Am Med Assoc 1952;149(8):729-34.</p><p>Hinz C., Lamont-Havers R., Cominsky B., Gaines L. Agranulocytosis following use of phenylbutazone (butazolidin); report of a case. J Am Med Assoc 1953;151(1):38-9.</p><p>Etess A., Jacobson A. Fatality due to agranulocytosis following use of phenylbutazone (butazolidin). J Am Med Assoc 1953;151(8):639-40.</p><p>Procter J., Evans R. Toxic effects of phenylbutazone. Lancet 1953;1(6769):1047.</p><p>Krainin P. Gastric ulcer with massive hemorrhage following use of phenylbutazone; report of a case. J Am Med Assoc 1953;152(1):31-2.</p><p>Beutler E., Bergenstal D. Perforated duodenal ulcer with neutropenia and death in a patient receiving phenylbutazone therapy. Gastroenterology 1953;25(1):72-4.</p><p>Poinso R., Monges H., Toci J., Allegre S. Perforation of latent gastric ulcer after four injections of phenylbutazone. Bull Mem Soc Med Hop Paris 1954;70(19-20):693-4.</p><p>Phenacetin. http://en.wikipedia.org/wiki/Phenacetin</p><p>Гук И.Н. Противовоспалительные средства в клинике внутренних болезней. ФАРМиндекс-Практик 2001;(2):41-71.</p><p>Botting R. Antipyretic therapy. Front Biosci 2004;9:956-66.</p><p>Australian experience of analgesia in the mid 20 th century. http://samhs.org.au/</p><p>Лоуренс Д., Бенитт П. Клиническая фармакология. Т.1. М.: Медицина, 1991;656 с.</p><p>Цитрамон. http://lekarstvennik.ru/spravochnik-lekarstv/ tsitramon</p><p>Андросова С.О., Николаев А.Ю. Анальгетическая нефропатия. Ревматология 1984;2:54-7.</p><p>Реальная энциклопедия медицинскихь наукь. Под ред. A. Eulenburg, издавалась в 1894-1902 гг. Т.17. СПб., 1986.</p><p>Leech D., Hunter W. An inquiry regarding the importance of ill-effects following the use of antipyrin, antifebrin, &amp; phenacetin conducted by the therapeutic committee of the British Medical Association. Br Med J 1894;1(1724):85-90.</p><p>New York’s phenacetin. Cal State J Med 1903;1(4):97.</p><p>Sneader W. The discovery of aspirin: a reappraisal. BMJ 2000;321(7276):1591-4.</p><p>Bayer. http://en.wikipedia.org/wiki/Bayer</p><p>Starko K. Salicylates and pandemic influenza mortality, 1918-1919. Pharmacology, Pathology, and Historic Evidence. Clin Infect Dis 2009;49(9):1405-10.</p><p>Диагностика и лечение внутренних болезней. Под ред. проф. Е.Е. Гогина. Т.1. М.: Медицина, 1996.</p><p>Справочник Харрисона по внутренним болезням. Под ред. К.Дж. Иссельбехера, Е. Браунвальда. М.: Медицина, 1997.</p><p>Мазуров Н. Аспирина нужно много. Мед новости 1996;13(28):10.</p><p>Hart F., Boardman P. Indometacin: a new non-steroidal anti-inflammatory agent. Br Med J 1963;2(5363):965-70.</p><p>Boardman P., Nuki G., Hart F. Ibuprofen in the treatment of rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 1967;26(6):560-1.</p><p>Meyers O., Quantock O., Joubert P. et al. A multicentre trial of Voltaren in the treatment of rheumatoid arthritis. S Afr Med J 1974;48(48):2013-7.</p><p>Douthwaite A., Lintott G. Gastroscopic observation of effect of aspirin and certain other substances on stomach. Lancet 1938;2:1222-5.</p><p>Levrat M., Lambert R. Digestive hemorrhages &amp; gastroduodenal ulcers caused by aspirin; concerning 52 cases. Presse Med 1958;66(87):1945-8.</p><p>Busson A., Bourdon R., Bard M., Bismuth V. Radio-clinical aspects of medicamentous gastro-duodenal ulcers. Arch Mal Appar Dig Mal Nutr 1964;53:614-21.</p><p>Darvill F., Voegtline J., Hoffman G. Multiple peptic ulcers after salicylate ingestion. Northwest Med 1966;65(6):495-7.</p><p>Roth J. Role of drug in production of gastroduodenal ulcer. JAMA 1964;187:419-22.</p><p>Нестеров И.А., Сигидин Я.А. Клиника коллагеновых болезней. М.: Медицина, 1966.</p><p>Cecil R. Артриты и старость. Bull New York Acad Med 1929; Jan (цит. по: Acta rheumatic. Государственное медицинское издательство, 1929; вып. 1).</p><p>Вельяминов Н.А. Учение о болезнях суставов. Л.: Руководства и научные пособия для высшей школы, 1924.</p><p>Голубов Н.Ф. Нозология заболеваний суставов. Итоги сорокалетних наблюдений. В кн.: Acta Medica, вып. 11. Харьков: Научная мысль, 1926.</p><p>Материалы Первого всесоюзного съезда ревматологов. М., 1971.</p><p>Kier J., Gendel B., Rich J. Perforated peptic ulcer during cortisone administration. Am Pract Dig Treat 1953;4(8):510-2.</p><p>Литвинов Л.Д., Литвинова М.Р. Гастроинтестинальные язвы, связанные с различными типами гормональной терапии (обзор литературы). Пробл эндокрин гормонотер 1963;9:110-2.</p><p>Turner F. Steroid ulcer. Report of 28 cases with review of literature and discussion of patogenesis. J Maine Med Assoc 1965;56:72-82.</p><p>Silverstein F., Feld A., Gilbert D. Upper gastrointestinal tract bleeding. Predisposing factors, diagnosis, and therapy. Arch Intern Med 1981;141(3 Spec No):322-7.</p><p>Gabriel S., Bombardier C. NSAID induced ulcers. An emerging epidemic? J Rheumatol 1990;17(1):1-4.</p><p>Fries J. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991;28 (Suppl.):6-10.</p><p>Ward M., Fries J. Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981 - 1996. J Rheumatol 1998;25(3):408-16.</p><p>Griffin M. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998;104(3A):23-9.</p><p>Singh G., Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999;56(Suppl.):18-24.</p><p>Morrissey J., Tanaka Y., Thorsen W. The relative value of the Olympus model GT-5 gastrocamera and Olympus model GT-F gastrocamera fiberscope. Gastrointest Endosc 1968;14(4):197-200.</p><p>Persyko L., Swift J., Venkatachalam B. et al. Diagnosis of pathological changes in the stomach by gastroscopy: still and cine colour photography using a new fiberoptic gastroscope. Can Med Assoc J 1969;100(23):1067-75.</p><p>Valman H., Parry D., Coghill N. Lesions associated with gastroduodenal haemorrhage, in relation to aspirin intake. Br Med J 1968;4(5632):661-3.</p><p>Edmar D. Effects of salicylates on the gastric mucosa as revealed by roentgen examination and the gastrocamera. Acta Radiol Diagn (Stockh) 1971;11(1):57-64.</p><p>Phillips S. Gastric and duodenal ulceration associated with aspirin ingestion. Gastrointest Endosc 1973;19(4):169-71.</p><p>Roth S., Bennett R. Nonsteroidal anti-inflammatory drug gastropathy. Recognition and response. Arch Intern Med 1987;147(12):2093-100.</p><p>Rebedea D. Medicamentous ulcer or medicamentous gastropathy? Med Interna (Bucur) 1969;21(7):877-80.</p><p>Roth S. From peptic ulcer disease to NSAID gastropathy. An evolving nosology. Drugs Aging 1995;6(5):358-67.</p><p>Graham D. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where we stand. Am J Gastroenterol 1996;91(10):2080-6.</p><p>Lanza F., Royer G., Nelson R. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med 1980;303:136-8.</p><p>Fries J., Miller S., Spitz P. et al. Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology 1989;96(2 Pt 2 Suppl.):647-55.</p><p>Fries J., Miller S., Spitz P. et al. Identification of patients at risk for gastropathy associated with NSAID use. J Rheumatol 1990;20(Suppl.):12-9.</p><p>Henry D., Lim L., Garcia Rodriguez L. et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996;312:1563-6.</p><p>Ивашкин В.Т. Патогенез гастропатий, обусловленных приемом нестероидных противовоспалительных препаратов. Рос журн гастроэнтерол гепатол 1994;1:11-4.</p><p>Гребнева Л.С., Насонова С.В., Цветкова Л.И. Побочные эффекты лечения нестероидными противовоспалительными средствами и пути их коррекции. Клин мед 1997;5:42-5.</p><p>Василенко В.Х., Цодиков Г.В., Минушкин О.Н. Влияние некоторых противоревматических средств на слизистую оболочку желудка. Клин мед 1971;1:3-9.</p><p>Ясиновский М.А., Остапчук Н.А. Осложнения со стороны желудочно-кишечного тракта во время антиревматической терапии. Тер арх 1968;40(9):17-25.</p><p>Денисов Л.Н., Сидельникова С.М., Павленко Т.М. и др. Опыт клинического изучения бруфена в ревматологической практике. В сб.: Результаты клинического изучения лекарственного препарата бруфена. М., 1973;27-32.</p><p>Цодиков Г.В., Денисов Л.Н., Акимова Т.Ф. и др. Слизистая оболочка желудка при действии на нее противоревматических медикаментов - аспирина, индометацина, бруфена, преднизолона. Вопр ревматол 1975;4:38-45.</p><p>Цодиков Г.В. Механизм и диагностика повреждений желудка, возникающих при лечении противоревматическими препаратами (клинико-морфологическое и экспериментальное исследование): Автореф дис.. д-ра мед наук. М., 1978.</p><p>Калинин А.В. Симптоматические гастродуоденальные язвы: Дис.. д-ра мед. наук. М., 1987.</p><p>Насонова В.А., Карасева Н.М., Хватов В.Б., Сигидин Я.А. Цитогенетическое исследование пациентов с ревматизмом в процессе лечения аспирином. Тер арх 1972;44(3):26-33.</p><p>Насонова В.А., Матулис А.А., Трофимова Т.М. Проблемы терапии заболеваний суставов (в соответствии с данными 4-го Конгресса ревматологов ГДР, Веймар, сентябрь, 11-13, 1974). Тер арх 1975;47(5):116-22.</p><p>Насонова В.А., Муравьев Ю.В., Насонов Е.Л. и др. Мультицентровое исследование эффективности и безопасности долгит-крема у больных с остеоартрозом. Тер арх 1995;67(6):48-50.</p><p>-й Европейский конгресс ревматологов. Тез. докладов. М., 1983.</p><p>Насонова В.А., Сигидин Я.А., Муравьев Ю.В. и др. Исследование использования препарата Артротек для лечения ревматических заболеваний. Тер арх 1995;67(1):34-8.</p><p>Современные проблемы ревматологии. Под ред. В.А. Насоновой. М.: ВНИИМИ, 1985;61 с.</p><p>Vane J. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231(25):232-5.</p><p>Botting R. Vane’s discovery of the mechanism of action of aspirin changed our understanding of its clinical pharmacology. Pharmacol Rep 2010;62(3):518-25.</p><p>Dajani E., Nissen C. Gastrointestinal cytoprotective effects of misoprostol. Clinical efficacy overview. Dig Dis Sci 1985;30(11 Suppl.):194-200.</p><p>Silverstein F., Kimmey M., Saunders D. et al. Gastric protection by misoprostol against 1,300 mg of aspirin. An endoscopic dose-response study. Am J Med 1987;83(1A):32-6.</p><p>Watkinson G., Akbar F. Misoprostol in peptic ulcer disease. Prostaglandins 1987;33(Suppl.):78-92.</p><p>Silverstein F. New strategies for the prevention of serious upper GI complication from NSAIDs: lessons from the MUCOSA trial. New Stand Arthr Care 1996;5:2-6.</p><p>Bolten W., Melo J., Stead H., Geis G. The gastroduodenal safety and efficacy of fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis. Br J Rheum 1992;31:753-8.</p><p>Fries J., Kristen N., Bennet M. et al. The rise and decline of nonsteroidal anti-inflammatory drag-associated gastropathy in rheumatoid arthritis. Arthr Rheum 2004;50:2433-40.</p><p>Black J., Duncan W., Durant C. et al. Definition and antagonism of histamine H2-receptors. Nature 1972;236(5347):385-90.</p><p>Brimblecombe R., Duncan W., Durant G. et al. The pharmacology of cimetidine, a new histamine H2-receptor antagonist. Br J Pharmacol 1975;53(3):435-6.</p><p>Simon B., Bergdolt H., Dammann H., Muller P. Ranitidine in the therapy and prevention of NSAR-induced (non-steroidal anti-rheumatic agents) gastroduodenal lesions in patients with rheumatism. Z Gastroenterol 1991;29:217-21.</p><p>Robinson M., Mills R., Euler A. Ranitidine prevents duodenal ulcers associated with non-steroidal anti-inflammatory drug therapy. Aliment Pharmacol Ther 1991;5:143-50.</p><p>Lancaster-Smith M., Jaderberg M., Jakson D. Ranitidine in the treatment of non-steroidal anti-inflammatory drug associated gastric and duodenal ulcers. Gut 1991;32:252-5.</p><p>Tildesley G., Ensanullah R., Wood J. Ranitidine in the treatment of gastric and duodenal ulcers associated with non-steroidal antiinflammatory drugs. Br J Rheumatol 1993;32:474-8.</p><p>Taha A., Hudon N., Hawkey C. et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996;334:1435-9.</p><p>Schackmann R., Schwartz A., Saccomani G., Sachs G. Cation transport by gastric H+:K+ ATPase. J Membr Biol 1977;32(3-4):361-81.</p><p>Fellenius E., Berglindh T., Sachs G. et al. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H++ K+)ATPase. Nature 1981;290(5802):159-61.</p><p>Muller P., Dammann H., Seitz H., Simon B. Effect of repeated, once daily, oral omeprazole on gastric secretion. Lancet 1983;1(8314-5):66.</p><p>Исаков В.А. Ингибиторы протонного насоса: их свойства и применение в гастроэнтерологии. М.: Академкнига, 2001.</p><p>Yeomans N., Tulassay Z., Juhasz L. et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998;338(11):719-26.</p><p>Hawkey C., Karrasch J., Szczepanski L. et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998;338(11):727-34.</p><p>McKeage K., Blick S., Croxtall J. et al. Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults. Drugs 2008;68(11):1571-607.</p><p>Hawkey C., Talley N., Yemans N. et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol 2005;100:1028-36.</p><p>Scheiman J., Yeomans N., Talley N. et al. Prevention of ulcer by esomeprazole in at-risk patients using non-selective NSAIDs or COX-2 inhibitor. Am J Gastroenterol 2006;101:701-10.</p><p>Chan F., Wong V., Suen B. et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007;369:1621-6.</p><p>Ткаченко Е.И., Успенский Ю.П., Каратеев Ф.Е. и др. Гастроэзофагеальная рефлюксная болезнь: патогенетические основы дифференцированной тактики лечения. Экспер клин гастроэнтерол 2009;2:104-15.</p><p>Каратеев А.Е., Насонова В.А. Энтеропатия, индуцированная нестероидными противовоспалительными препаратами. Тер арх 2003;5:74-8.</p><p>Goldstein J., Eisen G., Lewis B. et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005;3-13.</p><p>Adebayo D., Bjarnason I. Is non-steroidal anti-inflammaory drug (NSAID) enteropathy clinically more important than NSAID gastropathy? Postgrad Med J 2006;82(965):186-91.</p><p>Delvaux M., Gay G. Capsule endoscopy: technique and indications. Best Pract Res Clin Gastroenterol 2008;22(5):813-37.</p><p>Fu J., Masferrer J., Seibert K. et al. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990;265(28):16737-40.</p><p>Xie W., Chipman J., Robertson D. et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A 1991;88(7):2692-6.</p><p>Sirois J., Richards J. Purification and characterization of a novel, distinct isoform of prostaglandin endoperoxide synthase induced by human chorionic gonadotropin in granulosa cells of rat preovulatory follicles. J Biol Chem 1992;267(9):6382-8.</p><p>Vane J., Botting R. New insights into the mode of action of antiinflammatory drugs. Inflamm Res 1995;44(1):1-10.</p><p>Rainsford K. Profile and mechanisms of gastrointestinal and other side effects of nonsterodal anti-inflammatory drugs (NSAIDs). Am J Med 1999;107:27-36.</p><p>Furst D. Meloxicam: selective COX-2 inhibition in clinical practice. Semin Arthr Rheum 1997;26(6 Suppl.):21-7.</p><p>Hawkey C., Kahan A., Steinbru ck K. et al. Gastrointestinal tolerability of meloxicam compared diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheum 1998;37:1142-7.</p><p>Dequerker J., Hawkey C., Kahan A. et al. Improvement in gastrointestinal tolerability of selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large Scale Evaluation of COX inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 1998;37:946-51.</p><p>Gonzalez E., Patrignani P., Tacconelli S., Rodriguez L. Variability of risk of upper gastrointestinal bleeding among nonsteroidal anti-inflammatory drugs. Arthr Rheum 2010;62(6):1592-601.</p><p>Panara M., Renda G., Sciulli M. et al. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther 1999;290(1):276-80.</p><p>Van Hecken A., Schwartz J., Depre M. et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000;40(10):1109-20.</p><p>Capone M., Tacconelli S., Sciulli M., Patrignani P. Clinical pharmacology of selective COX-2 inhibitors. Int J Immunopathol Pharmacol 2003;16(2 Suppl.):49-58.</p><p>Singh G., Fort J., Goldstein J. et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-1 study. Am J Med 2006;119:255-66.</p><p>Cannon C., Curtis S., FitzGerald G. et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006;368(9549):1771-81.</p><p>Simon L., Weaver A., Graham D. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized control trial. JAMA 1999;282:1921-8.</p><p>Emery P., Zeidler H., Kvien T. et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized double-blind comparison. Lancet 1999;354:2106-11.</p><p>Hunt R., Harper S., Watson D. et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003;98(8):1725-33.</p><p>Laine L., Curtis S.P., Cryer B. et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007;369:465-73.</p><p>Silverstein F., Faich G., Goldstein J. et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxid long-term arthritis safety study. JAMA 2000;84:1247-55.</p><p>Chan F., Lanas A., Scheiman J. et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010;376:173-9.</p><p>Bresalier R., Sandler R., Quan H. et al. for the Adenomatous Polyp Prevention on Vioxx (APPROVEe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New Engl J Med 2005;352(11):1092-102.</p><p>Bombardier C., Laine L., Reicin A. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343(21):1520-8.</p><p>Horton R. Vioxx, the implosion of Merck, and aftershocks at the FDA. Lancet 2004;364(9450):1995-6.</p><p>Lenzer J. Crisis deepens at the US Food and Drug Administration. BMJ 2004;329(7478):1308.</p><p>Armstrong D. How the New England Journal missed warning signs on vioxx. Wall Street Journal 2006;15:рА1. http://online.wsj.com/article/SB114765430315252591.html</p><p>Насонов Е.Л. Анальгетическая терапия в ревматологии: путешествие между Сциллой и Харибдой. Клин фармакол тер 2003;12(1):64-9.</p><p>Grosser T., Fries S., FitzGerald G. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenes an opportunities. J Clin Invest 2006;16:41.</p><p>Hermann M. Cardiovascular risk associated with nonsteroidal anti-inflammatory drugs. Curr Rheumatol Rep 2009;11(1):31-5.</p><p>Nussmeier N., Whelton A., Brown M. et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352(11):1081-91.</p><p>Information for Healthcare Professionals: Valdecoxib (marketed as Bextra). FDA Alert (4/7/2005). http:// www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformati onforPatientsandProviders/ucm124649.htm</p><p>Lumiracoxib withdrawn in Australia. 14 August, 2007. http://www.prescriber.org.uk</p><p>Press release: European Medicines Agency recommends with-drawal of the marketing authorisations for lumiracoxib-containing medicines. 13 December, 2007. http: //www. emea. europa.eu</p><p>Lanas A., Tornero J., Zamorano J. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study. Ann Rheum Dis 2010;69(8):1453-8.</p><p>Rahme E., Roussy J., Lafrance J. et al. Use of nonsteroidal anti-inflammatory drugs: is there a change in patient risk profile after withdrawal of rofecoxib? J Rheumatol 2011;38(2):195-202.</p><p>Schneeweiss S., Glynn R., Avorn J. et al. NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib. Pharmacoepidemiol Drug Saf 2009;18(12):1134-42.</p><p>Barozzi N., Tett S. What happened to the prescribing of other COX-2 inhibitors, paracetamol and non-steroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia? Pharmacoepidemiol Drug Saf 2007;16(11):1184-91.</p><p>Fiorucci S., Distrutti E. COXIBs, CINODs and HВS-releasing NSAIDs: current perspectives in the development of safer non steroidal anti-inflammatory drugs. Curr Med Chem 2011;18(23):3494-505.</p><p>White W., Schnitzer T., Fleming R. et al. Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis. Am J Cardiol 2009;104(6):840-5.</p><p>Baerwald C., Verdecchia P., Duquesroix B. et al. Efficacy, safety, and effects on blood pressure of naproxcinod 750 mg twice daily compared with placebo and naproxen 500 mg twice daily in patients with osteoarthritis of the hip: a randomized, double-blind, parallel-group, multicenter study. Arthr Rheum 2010;62(12):3635-44.</p><p>Schnitzer T., Hochberg M., Marrero C. et al. Efficacy and safety of naproxcinod in patients with osteoarthritis of the knee: a 53-week prospective randomized multicenter study. Semin Arthr Rheum 2011;40(4):285-97.</p><p>Singh V., Patil C., Kulkarni S. Effect of licofelone against NSAIDs-induced gastrointestinal ulceration and inflammation. Indian J Exp Biol 2005;43(3):247-53.</p><p>Goldstein J., Hochberg M., Fort J. et al. Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone. Aliment Pharmacol Ther 2010;32(3):401-13.</p></div><br />